Margaret Martin

Margaret Martin has more than 14 years of experience in the healthcare space, including eight years serving as a senior policy advisor on the Senate Health, Education, Labor and Pensions (HELP) Committee advising on healthcare policy initiatives, leading negotiations and developing legislation. She has vast knowledge regarding policy and legislative issues related to products regulated by the Food and Drug Administration (FDA) including drugs, medical devices, food, tobacco and cosmetic products, as well as with public health preparedness and biodefense policies, including those overseen by the Biomedical Advanced Research and Development Authority (BARDA).

As a senior policy advisor on the HELP Committee, Margaret navigated complex political and congressional processes required to advance healthcare policy and legislation aimed at helping drive forward innovation in the private sector. She engaged and advocated on policy matters with Senate leadership, bipartisan congressional staff, members and staff of the Senate HELP and Finance Committees, the Energy & Commerce Committee, and other committees within the Senate and House of Representatives.

Margaret joins DLA Piper after serving most recently as the senior FDA policy advisor for Ranking Member Richard Burr. In this role, she led negotiations for and advised on policy issues related to the FDA and pandemic preparedness, including the FDA User Fee Reauthorization Act, which reauthorized the agency's medical product user fee programs through 2027; the Food and Drug Omnibus Reform Act, which included reforms to FDA's regulation of medical products; the Modernization of Cosmetics Regulation Act, which modernized FDA's authority to regulate cosmetic products; and the PREVENT Pandemics Act, which strengthened preparedness and response capabilities following the COVID-19 pandemic. She also led negotiations for the FDA Safety and Landmark Advancements Act and the Verifying Accurate Leading-edge IVCT Development (VALID) Act as part of the 2022 FDA user fee reauthorization packages.

Margaret Martin is not a lawyer.